Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI6570 after prior myocardial infarction with persistent inflammation
NL-OMON52059Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of golocdacimab in myocardial infarction (MI), coronary arteriosclerosis and heart failure (HF) (4 arms), sponsored by AstraZeneca. Primary endpoint: Effect on non-calcified coronary atherosclerotic plaques versus placebo. Started Aug 2021; status: completed.
02
Drugs
golocdacimab
03
Conditions
myocardial infarction (MI)coronary arteriosclerosisheart failure (HF)
Beyond the preview
Go deeper on NL-OMON52059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52059.